Down 70%: Is Prana Biotechnology Ltd. a Buy?
The biggest loser today in the biotech space was Prana Biotechnology , down a massive 70% because its candidate Alzheimer's drug PBT2 failed its phase 2 trial. The drug failed not only to improve cognitive function, but it also failed to affect what it was intended to, by not reducing amyloid plaques in patients. The company is also testing the drug for Huntington's disease, but early data aren't encouraging for that indication.
In this video, Motley Fool health-care analyst David Williamson looks at the future of Prana Biotechnology. He discusses a statement from the company's CEO that it will continue to develop PBT2, and gives investors his opinion on the stock today. David also looks at where future efforts to treat Alzheimer's disease are going to be focused.
6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
The article Down 70%: Is Prana Biotechnology Ltd. a Buy? originally appeared on Fool.com.
David Williamson owns shares of Merck. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.